PAVmed Restructures Capitalization to Remove Convertible Overhang and Accelerate EsoGuard Commercialization

PAVmed Restructures to Clear Legacy Overhang

PAVmed Inc. is recasting its capital structure to remove longstanding convertible securities that the company says have constrained its commercial strategy for its Lucid Diagnostics subsidiary and the EsoGuard esophageal DNA test. The company announces a package of financings and redemptions designed to simplify capitalization, shore up liquidity and support reimbursement and market access efforts for EsoGuard.

Financing Recast Aims to Accelerate EsoGuard Reimbursement and Commercialization

PAVmed closes financings that issue $30 million of Series D convertible preferred stock and concurrently places a $15 million senior secured note due February 2029. The Series D is accompanied by warrants exercisable for up to an additional $30 million of Series D upon publication of a positive draft Medicare local coverage determination (LCD) for EsoGuard. Gross proceeds are used immediately to redeem and retire all outstanding Series C convertible preferred stock and other convertible debt, removing a legacy overhang the company says impeded strategic execution.

Management frames the transaction as a move to reduce dilution risk and lower near‑term refinancing needs, thereby letting Lucid Diagnostics concentrate on reimbursement, commercialization and clinical adoption of EsoGuard. By simplifying capitalization, PAVmed expects to give shareholders clearer visibility into future equity value and to enable more focused execution of growth initiatives around the esophageal cancer screening test, which seeks Medicare local coverage to broaden clinical uptake.

The financings come from existing long‑term investors and leave PAVmed with approximately $7.7 million in net cash proceeds for working capital after redemptions, alongside the $15 million long‑term note. The company states that, if the warrants are exercised following a positive EsoGuard LCD and stockholder approval converts Series D into common stock, the balance sheet will consist largely of common equity and long‑term debt and could add about $37.7 million of incremental cash.

Governance and approval timeline

PAVmed schedules a special meeting of stockholders no later than April 30, 2026, to seek approval to convert the Series D preferred into common stock at a $6.50 conversion price. Management reports it has voting agreements from holders representing roughly 25% of outstanding common shares in support of the conversion proposal.

Industry and commercial implications

The company presents the move as materially strengthening its balance sheet and corporate stability, which it says positions Lucid and the EsoGuard program to better pursue reimbursement discussions with payers and accelerate commercialization efforts in an industry where coverage decisions critically affect clinical adoption.